These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions. Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333 [TBL] [Abstract][Full Text] [Related]
14. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512 [TBL] [Abstract][Full Text] [Related]
15. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. Jha MK; Wilkinson ST; Krishnan K; Collins KA; Sanacora G; Murrough J; Goes F; Altinay M; Aloysi A; Asghar-Ali A; Barnett B; Chang L; Costi S; Malone D; Nikayin S; Nissen SE; Ostroff R; Reti I; Wolski K; Wang D; Hu B; Mathew SJ; Anand A JAMA Netw Open; 2024 Jun; 7(6):e2417786. PubMed ID: 38916891 [TBL] [Abstract][Full Text] [Related]
16. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]